Psoriasis in the patient with human immunodeficiency virus, part 1: Review of pathogenesis

Cutis

Volumn 82, Issue 2, 2008, Pages 117-122

  Patel, Rita V ^a   Weinberg, Jeffrey M ^b,c,d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

^d College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PATHOLOGY; PSORIASIS; REVIEW; T LYMPHOCYTE;

CYTOKINES; HIV INFECTIONS; HUMANS; PSORIASIS; T-LYMPHOCYTES;

EID: 51049094229     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Duvic M, Johnson TM, Rapini RP, et al. Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome. Arch Dermatol. 1987;123:1622-1632.
2. Munoz-Perez MA, Rodrigea-Pichardo A, Camacho F, et al. Dermatological findings correlated with CD4 lymphocyte counts in a prospective 3 year study of 1161 patients with human immunodeficiency virus disease predominantly acquired through intravenous drug abuse. Br J Dermatol. 1989;139:33-39.
3. Badger J, Berger TG, Gambia C, et al. HIV and psoriasis. Clin Rev Allergy Immunol. 1996;14:417-431.
4. Colebunders R, Blot K, Meriens V, et al. Psoriasis regression in terminal AIDS [letter]. Lancet. 1992;339:1110.
5. Jaffee D, May LP, Sanchez M, et al. Staphylococcal sepsis in HIV antibody seropositive psoriasis patients. J Am Acad Dermatol. 1991;24:970-972.
6. King LE, Dufresne RG, Lovette GL, et al. Erythroderma: review of 82 cases. South Med J. 1986;79:1210-1215.
7. Obuch ML, Maurer TA, Becker B, et al. Psoriasis and human immunodeficiency virus infection. J Am Acad Dermatol. 1992;25:667-673.
8. Myskowski PL, Ahkami R. Dermatologic complications of HIV infection. Med Clinic North Am. 1996;80:1415-1435.
9. Fife DJ, Waller JM, Jeffes EW, et al. Unraveling the paradoxes of HIV-associated psoriasis: a review of T-cell subsets and cytokine profiles. Dermatol Online J. 2007;13:4.
10. Ortonne JP, Lebwohl M, Griffiths C; Alefacept Clinical Study Group. Alefacept-induced decrease in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol. 2003;13:117-123.
11. Ellis CN, Krueger GG; Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001;345:248-255.
12. Klein SA, Dobmyer JM, Pape M, et al. Demonstration of the Thl and Thl cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on signal cell level by flow cytometry. AIDS. 1997;11:111-118.
13. H1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol. 1999;113:752-759.
14. + subsets. J Invest Dermatol. 1998;111:1072-1078.
15. Friedrich M, Krammig S, Henze M, et al. Flow cytometric characterization of lesions T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res. 2000;292:519-521.
16. Mallon E, Bunker CB. HIV-associated psoriasis. AIDS Patient Care and STDS. 2000;14:239-246.
17. Mallon E, Young D, Bunce M, et al. HLA-Cw*0602 and HIV-associated psoriasis. Br J Dermatol. 1998;139:527-533.
18. Trembath RC, Clough RL, Rosblotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet. 1997;6:813-820.
19. Schendel D, Reinhardt C, Necson P, et al. Cytotoxic T lymphocytes show recognition of EBV-bearing cells and allorecognition of HLA class I molecules presenting self peptides. J Immunol. 1992;149:2406-2414.
20. Harrer T, Harrer E, Kalams S, et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. J Immunol. 1996;156:2616-2623.
21. Johnson RP, Trocha A, Buchanan TM, et al. Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T lymphocyte clone. J Virol. 1993;67:438-445.
22. Mallon E, Bunce M, Wojnarowska F, et al. HLA-CW*0602 is a susceptibility factor in type I psoriasis, and evidence Ala-73 is increased in male type I psoriatics. J invest Dermatol. 1997;109:183-186.
23. Gonzalez S, Martinez-Borra J, Del Rio JS, et al. The OFT3 gene polymorphism confers susceptibility to psoriasis independent of the association of HLA-Cw*0602. J invest Dermatol. 2000;115:824-828.
24. Baker BS, Griffiths CE, Lambert S, et al. The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br J Dermatol. 1987;116:503-510.
25. Cameron AL, Kirby B, Fei W, et al. Natural killer and natural killer-T cells in psoriasis. Arch Dermatol Res. 2002;294:363-369.
26. Austin LM, Coven TR, Bhardwaj N, et al. Intraepidermal lymphocytes in psoriatic lesions are activated GMP-17(TIA-1)+CD8+CD3 + CTLs as determined by phenotypic analysis. J Cutan Pathol. 1998;25:79-88.
27. +) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol. 2004;150:852-859.
28. Namazi MR. Paradoxical exacerbation of psoriasis in AIDS: proposed explanations including the potential roles of substance P and gram-negative bacteria. Autoimmunity. 2004;37:67-71.
29. Henseler T. The genetics of psoriasis. J Am Acad Dermatol. 1997;37(2,pt3 ):S1-S11.
30. Duvic M. Immunology of AIDS related to psoriasis. J Invest Dermatol. 1990;95(suppl 5):S38-S40.
31. Arnett FC, Reveille JD, Duvic M. Psoriasis and psoriatic arthritis associated with human immunodeficiency virus infection. Rheum Dis Clin North Am. 1991;17:59-78.
32. Roederer M, Dubs JG, Anderson MT, et al. CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin invest. 1995;95:2061-2066.
33. + lymphocytes by human immunodeficiency virus type 1 in vivo. J Virol. 2001;75:4091-4102.
34. + memory T cells are the predominant population of IV-1-infected lymphocytes in neonates and children. AIDS. 1996;10:1477-1484.
35. Spina CA, Prince HE, Richman DD. Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. J Clin invest. 1997;99:1774-1785.
36. Mosmann T, Cherwinski H, Bond M, et al. Two types of murine helper T cell clones, I. definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136:2348-2357.
37. Modlin R. Thl-Th2 paradigm: insights from leprosy. J Invest Dermatol. 1994;102:828-832.
38. Uyemura K, Yamamura M, Fivenson DF, et al. The cytokine network in lesionai and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993;101:701-705.
39. Schlaak J, Busulau M, Jochum W, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol. 1994;102:145-149.
40. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, et al. Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. J Invest Dermatol. 1995;105 (suppl 1):S89-S94.
41. Prinz JC, Gross B, Vollmer S, et al. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur J Immunol. 1994;24: 593-598.
42. + T cells in chronic plaque psoriasis are Tcl cells producing heterogeneous levels of interferon-gamma. Exp Dermatol. 2001;10:168-174.
43. Clerici M, Shearer GM. A TH1 TH2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993;14:107-111.
44. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today. 1994;15:575-581.
45. Fuchs D, Hausen A, Reibnegger G, et al. Psoriasis, gammainterferon, and the acquired immunodeficiency syndrome [letter]. Ann intern Med. 1987;106:165.
46. Breuer-McHam JN, Marshall GD, Lewis DE, et al. Distinct serum cytokines in AIDS-related skin diseases. Viral Immunol. 1998;11:215-220.
47. Breuer-McHam JN, Ledbetter LS, Sarris AH, et al. Cytokine expression patterns distinguish HIV associated skin diseases. Exp Dermatol. 2000;9:341-350.
48. Murphy GF, Shepard RS, Harrist TJ, et al. Ultrastructural documentation of HLA-DR antigen reactivity in normal human acrosyringial epithelium. J invest Dermatol. 1983;81:181-183.
49. Aubock J, Romani N, Grubauer G, et al. HLA-DR expression on keratinocytes is a common feature of diseased skin. Br J Dermatol. 1986;114:465-472.
50. Terui T, Aiba S, Kato T, et al. HLA-DR antigen expression on keratinocytes in highly inflamed parts of psoriatic lesions. Br J Dermatol. 1987;116:87-93.
51. Griffiths CE, Voorhees JJ, Nickoloff BJ. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol. 1989;20:617-629.
52. Nickoloff BJ. Role of interferon-gamma in cutaneous trafficking of lymphocytes with emphasis on molecular and cellular adhesion events. Arch Dermatol. 1988;124:1835-1843.
53. Barker JN, MacDonald DM. Cutaneous lymphocyte trafficking in the inflammatory dermatoses. Br J Dermatol. 1992;126:211-215.
54. Travers JB, Hamid QA, Norris DA, et al. Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis. J Clin Invest. 1999;104:1181-1189.
55. Nickoloff BJ, Mitra RS, Green J, et al. Accessory cell function of keratinocytes for superantigens. dependence on lymphocyte function-associated antigen-1/ intercellular adhesion molecule-1 interaction. J Immunol. 1993;150:2148-2159.
56. Tokura Y, Yagi J, O'Malley M, et al. Superantigenic staphylococcal exotoxins induce T-cell proliferation in the presence of Langerhans cells or class II-bearing keratinocytes and stimulate keratinocytes to produce T-cell-activating cytokines. J Invest Dermatol. 1994;102:31-38.
57. Ezepchuk YV, Leung DY, Middleton MH, et al. Staphylococcal toxins and protein A differentially induce cytotoxicity and release of tumor necrosis factor-alpha from human keratinocytes. J Invest Dermatol. 1996;107:603-609.